BCYC - Goldman likes Bicycle Therapeutics in premarket analyst action September, 11 2019 07:03 AM Bicycle Therapeutics plc Oramed Pharmaceuticals (NASDAQ:ORMP) initiated with Buy rating and $7 (136% upside) at Ladenburg Thalmann. Shares up 3% premarket.More news on: Oramed Pharmaceuticals Inc., PhaseBio Pharmaceuticals, Inc., Bicycle Therapeutics plc, Healthcare stocks news, Stocks on the move, , Read more ...